$CHTP Recent Headlines Wednesday’s movers: Herbalife

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2014 at 9:51 AM

$CHTP Recent Headlines

Wednesday’s movers: Herbalife slumps after call 4:57 p.m. Feb. 20, 2013 - Sue Chang
Chelsea Therapeutics CEO, other execs step down 6:17 a.m. July 10, 2012 - MarketWatch.com
Thursday’s biggest gaining and declining stocks 12:00 p.m. May 31, 2012 - MarketWatch
Chelsea shares tumble on FDA setback 9:53 a.m. March 29, 2012 - MarketWatch.com
FDA seeks more info from Chelsea Therapeutics 7:22 a.m. March 29, 2012 - Greg Morcroft
Chelsea Therapeutics falls 23% in premarket 7:04 a.m. March 29, 2012 - Steve Gelsi
FDA decision nears for Chelsea Therapeutics 11:10 a.m. March 14, 2012 - MarketWatch.com
Friday’s biggest gaining and declining stocks 4:40 p.m. Feb. 24, 2012 - Kate Gibson
Chelsea Therapeutics soars on FDA nod 1:13 p.m. Feb. 24, 2012 - Val Brickates Kennedy
Chelsea Therapeutics up 71% in premarket 7:58 a.m. Feb. 24, 2012 - Steve Gelsi
Stocks to watch Friday: Deckers, Salesforce, Crocs 6:49 a.m. Feb. 24, 2012 - MarketWatch
Monday’s biggest gaining and declining stocks 4:51 p.m. Feb. 13, 2012 - MarketWatch
Chelsea plunges 36% ahead of FDA update 10:54 a.m. Feb. 13, 2012 - Val Brickates Kennedy
Chelsea Therapeutics jumps 8% on ADHD study 11:15 a.m. July 26, 2011 - Val Brickates Kennedy
Biogen, Acura lead drug stocks north 2:54 p.m. June 20, 2011 - Val Brickates Kennedy
Friday’s biggest advancing & declining stocks 2:55 p.m. June 10, 2011 - Kate Gibson
Drug stocks follow broader market south 12:10 p.m. June 10, 2011 - Val Brickates Kennedy
Chelsea Therapeutics soars on price target upgrade 9:01 a.m. June 10, 2011 - Val Brickates Kennedy
Monday’s biggest advancing and declining stocks 12:27 p.m. April 18, 2011 - MarketWatch
Wednesday’s biggest gaining and declining stocks 6:05 p.m. Feb. 2, 2011 - Kate Gibson

Chelsea Therapeutics (CHTP) in Focus: Stock Tumbles 7.5% - Tale of the Tape 52 min ago - Zacks.com
Chelsea Therapeutics: The Good, The Bad And The Ugly 8:55 a.m. Feb. 13, 2014 - Seeking Alpha
Chelsea Therapeutics +2.6%, Feuerstein predicts Northera FDA approval 10:29 a.m. Feb. 12, 2014 - Seeking Alpha
Prediction: Chelsea Wins Northera FDA Approval Friday 9:41 a.m. Feb. 12, 2014 - TheStreet.com
Chelsea: Trading Strategies For The Pending FDA Decision 11:48 a.m. Feb. 11, 2014 - Seeking Alpha
Chelsea Therapeutics: My Valentine's Day Dream Date? 11:31 a.m. Feb. 7, 2014 - Seeking Alpha
Does Accuray's Recent Unusual Bullish Options Activity Signal A Rally In The Stock Soon? 7:50 a.m. Jan. 28, 2014 - Seeking Alpha
Telecom Industry Stock Outlook - Jan 2014 - Zacks Analyst Interviews 5:37 a.m. Jan. 21, 2014 - Zacks.com
Telecom Industry Stock Outlook - Jan 2014 - Industry Outlook 5:37 a.m. Jan. 21, 2014 - Zacks.com
J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech 3:30 p.m. Jan. 17, 2014 - TheStreet.com
A Few Minutes With Chelsea's CEO on Tuesday's Northera Panel and Future Plans 10:33 a.m. Jan. 17, 2014 - TheStreet.com
Stocks You Wish You Owned on January 15 10:42 p.m. Jan. 16, 2014 - WallStreetSectorSelector
Chelsea Therapeutics May Be A Revenue Generating Biotech By The End Of 2014 3:02 p.m. Jan. 16, 2014 - Seeking Alpha
Company news for January 16, 2014 - Corporate Summary 10:06 a.m. Jan. 16, 2014 - Zacks.com
Chelsea Therapeutics International (CHTP) Soars: Stock Up 91.7% - Tale of the Tape 9:39 a.m. Jan. 16, 2014 - Zacks.com
FDA Panel Backs CHTP's Northera - Analyst Blog 6:10 p.m. Jan. 15, 2014 - Zacks.com
Can Chelsea Live Up to Its Potential This Time? 11:20 a.m. Jan. 15, 2014 - 247WallSt.com
2 Biotech Stocks in Play: Celsion and Chelsea 11:14 a.m. Jan. 15, 2014 - Wall St. Cheat Sheet
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog 9:31 a.m. Jan. 15, 2014 - Zacks.com
CHTP Stock – Chelsea Therapeutics Passes FDA Test, Stock Skyrockets 5:19 a.m. Jan. 15, 2014 - InvestorPlace.com

Hypotension Global Clinical Trials Review, H1, 2014 10:23 a.m. Feb. 13, 2014 - PR Newswire - PRF
Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer 7:01 a.m. Jan. 30, 2014 - GlobeNewswire
Real Good Solar Takes On New Name, Ticker Symbol and Strategy: Real Goods Solar Inc. (NASDAQ:RSOL), Atossa Genetics Inc. (NASDAQ: ATOS), Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP) 8:02 a.m. Jan. 28, 2014 - ACCESSWIRE
Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director 7:00 a.m. Jan. 27, 2014 - GlobeNewswire
Early 2014 Advancing Companies with Expansion & New Distribution Opportunities: RiceBran, Whole Foods, Hain Celestial, DryShips and Chelsea Therapeutics 9:05 a.m. Jan. 16, 2014 - PR Newswire - PRF
Opening Buzzers: Chelsea Therapeutics International, Tesla Motors Inc, NQ Mobile Inc, Rexahn Pharmaceuticals 11:02 a.m. Jan. 15, 2014 - ACCESSWIRE
FDA Advisory Panel Recommends Approval of Chelsea Therapeutics' NORTHERA(TM) (Droxidopa) for the Treatment of Symptomatic nOH 5:09 p.m. Jan. 14, 2014 - GlobeNewswire
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis 8:00 a.m. Jan. 6, 2014 - PR Newswire
Announcements, Studies, and Corporate Updates by Healthcare Companies - Research Report on Horizon Pharma, Novavax, WuXi PharmaTech, Chelsea Therapeutics, and Anika Therapeutics 8:00 a.m. Dec. 24, 2013 - PR Newswire
Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray 8:34 a.m. Dec. 19, 2013 - PR Newswire
Chelsea Therapeutics Announces First Patient Dosed in NORTHERA(TM) (droxidopa) Study 401 for the Treatment of Symptomatic nOH 7:00 a.m. Dec. 9, 2013 - GlobeNewswire
Today's Research: ZIOPHARM Oncology Inc., Antares Pharma Inc., Chelsea Therapeutics Intl. Ltd, and Accuray Inc. 1:29 p.m. Nov. 22, 2013 - PR Newswire
Study Results, Private Placements, Collaborations, Product Launches, and Public Offerings - Research Report on ViroPharma, Incyte, Tenet Healthcare, Sagent Pharmaceuticals and Chelsea Therapeutics 8:00 a.m. Nov. 22, 2013 - PR Newswire
Chelsea Therapeutics Completes Public Offering of Common Stock 10:32 a.m. Nov. 18, 2013 - GlobeNewswire
BBEP, CHTP, XGTI and SNTA added to NASDAQ Active Stock Watch List at GSR 10:33 a.m. Nov. 13, 2013 - ACCESSWIRE
Chelsea Therapeutics Announces Pricing of Public Offering of Common Stock 8:45 a.m. Nov. 13, 2013 - GlobeNewswire
Chelsea Therapeutics Announces Public Offering of Common Stock 5:50 p.m. Nov. 12, 2013 - GlobeNewswire
Chelsea Therapeutics Reports Third Quarter 2013 Financial Results 4:23 p.m. Nov. 5, 2013 - GlobeNewswire
Morning Research: Antares Pharma Inc., Chelsea Therapeutics Intl. Ltd, Accuray Inc., and ZIOPHARM Oncology Inc. 8:11 a.m. Oct. 30, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Shaky Ground in Securities Fraud Suit

Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...

Doppel's Strategic Expansion: Adding PropRise Innovators

Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...

Johnsonville's Election Effort: Sausage for Dinner Gains Momentum

Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...

Silvercorp Updates El Domo Budget Amid Challenges

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Historic Surge: Women Veterans Join 120th Congress

The Winds of Change Are Blowing Through Washington It looks like the face of Congress is getting a combat-ready makeover with the latest election results. Veterans are stepping up to the plate, claiming at least 79 seats in the 120th Congress, with a historic presence of women veterans making waves. Yeah, we're talking about 11 women veterans hitting the halls of power,...

Life with PAH: A Journey of Awareness and Hope

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

The Braff Group's 400th Health Care M&A Milestone

No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...

Citius Unveils Promising LYMPHIR Data at EORTC Conference

A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...

Webull Corp Caught in Legal Storm; Investors Take Note

A Legal Storm Brewing It's like walking into a saloon, expecting a smooth drink, only to find a bar fight breaking out in front of you. That's the scene with Webull Corporation (NASDAQ: BULL) right now. This time, they ain't just shooting the breeze; they're in the line of legal fire. SBS Law, a heavyweight in shareholder rights, is rallying the troops for a class action...

NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...